|
|
LTK63 Vaccine Mutant Adjuvant |
|
Vaxjo ID |
19 |
|
Vaccine Adjuvant Name |
LTK63 Vaccine Mutant Adjuvant |
|
Adjuvant VO ID |
VO_0001251
|
|
Description |
The mutant of Escherichia coli heat-labile toxin (LT), LTK63, which lacks ADP-ribosylating activity, act as a potent mucosal adjuvants for the nasal delivery of an acellular pertussis (Pa) vaccine (Ryan et al., 1999). |
|
Stage of Development |
Clinical Trial |
|
Components |
LTK63 is a mutant of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant (Marchetti et al., 1998). |
|
Dosage |
In a study, groups of six 6–8 weeks old female BALB/c mice were given 1 μg or 10 μg LTK63 (Ryan et al., 1999). |
|
Function |
LTK63 enhance antigen-specific serum immunoglobulin G (IgG), secretory IgA, and local and systemic T-cell responses.(Ryan et al., 1999) |
| Related Vaccine(s) |
|
| References |
Marchetti et al., 1998: Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S, Covacci A, Massari P, Pagliaccia C, Manetti R, Telford JL, Douce G, Dougan G, Rappuoli R, Ghiara P. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 1998; 16(1); 33-37. [PubMed: 9607006].
Ryan et al., 1999: Ryan EJ, McNeela E, Murphy GA, Stewart H, O'hagan D, Pizza M, Rappuoli R, Mills KH. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infection and immunity. 1999; 67(12); 6270-6280. [PubMed: 10569737].
|
|
